Exelixis pained by FDA SPA no-show but pushes ahead with cabozantinib
01 November 2011
Sukaina Virji
Please Login to read the full article.
01 November 2011
Sukaina Virji
Please Login to read the full article.
RELATED CONTENT
NEWS
- Death and competition cause Exelixis dive on positive cabozantinib data in solid cancers
- Placebo patients to be offered Algeta's Alpharadin after efficacy in cancer trial
- Exelixis 3-month delay for cabozantinib data in medullary thryoid cancer
- Exelixis gains $12m upfront in Merck PI3K-delta deal
EVENTS
Today
The Rembrandt Hotel, London
07 June 2012
The Rembrandt Hotel, London
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
